mitoxantrone and Benign Neoplasms studies

Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.

Research Excerpts

Excerpt	Relevance	Reference
"From 11/87 until 7/90 103 patients entered a prospective randomized trial on the treatment of malignant pleural effusions (MPE) with intrapleural mitoxantrone versus placebo (pleural tube alone with instillation of isotonic NaCl)."	9.07	Intrapleural palliative treatment of malignant pleural effusions with mitoxantrone versus placebo (pleural tube alone). ( Gatzemeier, U; Groth, G; Häussingen, K; Heckmayr, M; Magnussen, H; Neuhauss, R; Pavel, JV, 1991)
"To assess the therapy-related risk of malignancies in mitoxantrone-treated patients with multiple sclerosis."	7.83	Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study. ( Buttmann, M; Mäder, U; Seuffert, L; Toyka, KV, 2016)
"Mitoxantrone is an anthracenedione, showing structural similarities to doxorubicin."	5.27	An EORTC phase II study of mitoxantrone in solid tumors and lymphomas. ( Armand, JP; Bastit, P; Cappelaere, P; De Jager, R; Earl, H; Fargeot, P; Keiling, R; Renard, J; Rubens, R; van Glabbeke, M, 1984)
"We have recently evaluated the combination of raltitrexed, levofolinic acid (LFA) and 5-fluorouracil (5-FU) in advanced head and neck and colorectal cancer, and we have shown that this combination is well tolerated and has clinical activity."	5.09	Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours. ( Avallone, A; Caponigro, F; Comella, G; Comella, P; De Rosa, V; Ionna, F; Rivellini, F, 2001)
"From 11/87 until 7/90 103 patients entered a prospective randomized trial on the treatment of malignant pleural effusions (MPE) with intrapleural mitoxantrone versus placebo (pleural tube alone with instillation of isotonic NaCl)."	5.07	Intrapleural palliative treatment of malignant pleural effusions with mitoxantrone versus placebo (pleural tube alone). ( Gatzemeier, U; Groth, G; Häussingen, K; Heckmayr, M; Magnussen, H; Neuhauss, R; Pavel, JV, 1991)
"A phase II clinical trial of an anthraquinone, mitoxantrone was performed in a total of 31 patients with various advanced solid tumors and 2 patients with malignant lymphomas refractory to extensive prior chemotherapies."	5.05	[Phase II study of mitoxantrone]. ( Adachi, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Nakada, H; Ogawa, M; Okada, Y; Tada, A; Usui, N, 1984)
" In addition, characterization of the UGT1A locus and genetic studies directed at understanding the role of bilirubin glucuronidation and the biochemical basis of the clinical symptoms found in unconjugated hyperbilirubinemia have uncovered the structural gene polymorphisms associated with Crigler-Najjar's and Gilbert's syndrome."	4.80	Human UDP-glucuronosyltransferases: metabolism, expression, and disease. ( Strassburg, CP; Tukey, RH, 2000)
"Mitoxantrone (MXT) is an androstenedione that is used to treat cancers and progressive forms of multiple sclerosis; however, its use is limited by its cardiotoxicity."	3.85	Pituitary adenylate cyclase-activating polypeptide (PACAP) protects against mitoxantrone-induced cardiac injury in mice. ( Bradley, J; Burn, B; Chuang, G; Coy, DH; Maderdrut, JL; Subramaniam, V; Varner, KJ; Xia, H, 2017)
"To assess the therapy-related risk of malignancies in mitoxantrone-treated patients with multiple sclerosis."	3.83	Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study. ( Buttmann, M; Mäder, U; Seuffert, L; Toyka, KV, 2016)
"Mitoxantrone is an important new agent with antitumor activity in leukemia, lymphoma, and breast cancer."	3.76	Mitoxantrone: a novel anthracycline derivative. ( Eble, M; Koeller, J, 1988)
"Serial assessment of ventricular function by means of radionuclide angiography was performed in 50 patients with malignant neoplasms who received either 4'-epidoxorubicin or mitoxantrone for longer than 3 months."	3.67	Assessment of ventricular function by radionuclide angiography in patients receiving 4'-epidoxorubicin and mitoxantrone. ( Falkson, G; Iturralde, M; Vorobiof, DA, 1985)
"Cardiotoxicity is among the most important adverse effects of childhood cancer treatment."	3.01	Acute and early-onset cardiotoxicity in children and adolescents with cancer: a systematic review. ( Bolier, M; Feijen, EAM; Grotenhuis, HB; Hoesein, FAAM; Kouwenberg, TW; Kremer, LCM; Mavinkurve-Groothuis, AMC; Netea, SA; Slieker, MG; van Dalen, EC, 2023)
" Samples for pharmacokinetic studies were collected."	2.79	Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy. ( Du, P; Gui, L; Han, X; Li, C; Li, N; Liu, P; Shi, Y; Song, Y; Yang, J; Zhang, S; Zhao, X, 2014)
"To find the maximum tolerated dose (MTD) of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors."	2.76	A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. ( Boinpally, R; Carducci, MA; Eisenberger, MA; Franke, A; King, S; Pili, R; Porter, J; Resta, LP; Spitz, A; Sweeney, CJ, 2011)
"Thirty-one patients with advanced solid tumors received two cycles of high-dose mitoxantrone (20-30 mg/m2) plus high-dose cyclophosphamide (3000-4000 mg/m2)."	2.70	High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: a phase I trial. ( Arcediano, A; Colomer, R; Cortés-Funes, H; Gómez-Martin, C; Hornedo, J; Mendiola, C; Pérez-Gracia, JL; Ruiz-Casado, A; Tornamira, MV; Valentin, V, 2001)
"Mitoxantrone (Novantrone) is an anthracene derivative that has demonstrated antitumor activity in patients with breast cancer, ovarian cancer, acute leukemia, and lymphoma."	2.69	A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors. ( Bigley, J; Burris, HA; Dieras, V; Eckardt, JR; Hardy, J; Hohneker, J; Jones, SF; Peacock, NW; Rodriguez, GI; Smith, L; Von Hoff, DD, 1998)
" Because both P-glycoprotein- and platinum-induced resistance appear to be clinically important and can be reversed in vitro with a short exposure of cyclosporin A (CSA) at 2000 and 5000 ng/ml, respectively, we undertook a trial of high-dose chemotherapy with carboplatin (1500mg/m2), mitoxantrone (75 mg/m2), and cyclophosphamide (120 mg/kg) over a 5-day period combined with escalating doses of CSA."	2.68	High-dose chemotherapy combined with escalating doses of cyclosporin A and an autologous bone marrow transplant for the treatment of drug-resistant solid tumors: a phase I clinical trial. ( Bayer, R; Camarda, M; Kinch, L; Loutfi, S; Peace, D; Rad, N; Sosman, J; Stiff, PJ; Tan, S, 1995)
" However, in vitro data demonstrate a steep dose-response curve to a variety of agents, most notably mitoxantrone."	2.67	Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma. ( Alberts, DS; Dolan, JR; McCloskey, T; McKenzie, RS; Rad, N; Sosman, JA; Stiff, PJ, 1994)
" Ten dogs were given mitoxantrone at a dosage of 5."	2.67	Toxicoses associated with the administration of mitoxantrone to dogs with malignant tumors: a dose escalation study. ( Atwater, SW; Bergman, PJ; Chen, C; Ciekot, PA; Moore, AS; Ogilvie, GK; Walters, LM, 1994)
"Mitoxantrone has recently been tested to treat effusions, and preliminary results suggest the high efficacy of this drug in the treatment of peritoneal, pericardial and pleural effusions."	2.67	Management of peritoneal effusions with intracavitary mitoxantrone or bleomycin. ( Maiche, AG, 1994)
"Mitoxantrone was administered at doses of 12, 21, 28, 32, 37, and 48 mg/m2 on day 1; GM-CSF (5 micrograms/kg once or twice daily) was administered on days 2 to 14."	2.67	Phase I trial of mitoxantrone and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid malignancies. ( Alberti, D; Arzoomanian, R; Schiller, JH; Spriggs, D; Storer, B; Tutsch, K, 1993)
"Mitoxantrone metabolites were detected in the plasma of five patients receiving high-dose mitoxantrone and in one with hepatic impairment."	2.67	Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation. ( Blaise, D; Cano, JP; Gaspard, MH; Iliadis, A; Just-Landi, S; Launay-Iliadis, MC; Maraninchi, D; Richard, B; Stoppa, AM; Viens, P, 1992)
" every 3 weeks in escalating doses combined with a fixed dose of s."	2.67	Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumors. ( Dal Fior, S; Favretto, S; Gasparini, G; Panizzoni, GA; Pozza, F; Von Hoff, DD, 1991)
"Mitoxantrone has been administered to more than 4000 patients worldwide."	2.65	Clinical safety and tolerance of mitoxantrone. ( Crossley, RJ, 1984)
" While clinical efficacy was limited with the viral mutants alone, outcomes were improved in combination with chemotherapeutics."	2.45	Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics. ( Halldén, G, 2009)
"Mitoxantrone is a synthetic anthraquinone that is active in the therapy of a number of malignancies."	2.38	Mitoxantrone: potential for use in intensive therapy. ( Herzig, R; LeMaistre, CF, 1990)
"Mitoxantrone is an antitumor agent that was synthesized to try to develop a doxorubicinlike drug with a better therapeutic index."	2.38	Mitoxantrone: its development and role in clinical practice. ( Weiss, RB, 1989)
"Mitoxantrone displays an improved tolerability profile compared with doxorubicin and other anthracyclines, although myelosuppression may occur more frequently."	2.38	Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. ( Balfour, JA; Chrisp, P; Faulds, D; Langtry, HD, 1991)
"Mitoxantrone is an anthraquinone antineoplastic agent with structural similarities to doxorubicin."	2.37	Mitoxantrone. ( Poirier, TI, 1986)
"Quercetin (QT) is a very effective anticancer drug in combating breast cancer."	1.91	Delivery of quercetin for breast cancer and targeting potentiation via hyaluronic nano-micelles. ( Li, M; Lin, K; Liu, Z; Sun, J; Wang, W; Wang, Z; Zhang, S; Zhao, Y; Zhen, Y, 2023)
"Its presence in cancer cells has positioned this receptor as a primary target for the development of novel anti-cancer agents."	1.91	Rational Design, Synthesis and Binding Affinity Studies of Anthraquinone Derivatives Conjugated to Gonadotropin-Releasing Hormone (GnRH) Analogues towards Selective Immunosuppression of Hormone-Dependent Cancer. ( Biniari, G; Karageorgos, V; Liapakis, G; Markatos, C; Nteli, A; Petrou, P; Pirmettis, I; Simal, C; Tselios, T; Tzoupis, H; Venihaki, M; Vlamis-Gardikas, A, 2023)
"Several successful anticancer chemotherapeutics have the property to induce immunogenic cell death (ICD), thereby causing anticancer immune responses."	1.48	eIF2α phosphorylation is pathognomonic for immunogenic cell death. ( Bezu, L; Forveille, S; Garcia, P; Gomes-da-Silva, LC; Humeau, J; Iribarren, K; Kepp, O; Kroemer, G; Liu, P; Sauvat, A; Senovilla, L; Zhao, L; Zitvogel, L, 2018)
"Cabozantinib (XL184) is a small molecule tyrosine kinase receptor inhibitor, which targets c-Met and VEGFR2."	1.46	Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib. ( Barbuti, AM; Chen, ZS; Wang, YJ; Wen, AW; Wurpel, JND; Yu, XY; Zhang, GN; Zhang, YK; Zhu, XJ, 2017)
"Noscapine has since been discovered to arrest cells at mitosis, albeit with moderately weak activity."	1.42	Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents. ( Capuano, B; DeBono, A; Scammells, PJ, 2015)
"Moreover, we found that a subset of cancer patients of various cancer-types indeed possessed CALRlow or CRTlow-tumours."	1.42	Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal. ( Agostinis, P; de Witte, P; Elsen, S; Garg, AD; Krysko, DV; Vandenabeele, P, 2015)
"However, subpopulations of cancer cells are either resistant to or can develop resistance to TRAIL-induced death."	1.40	Sensitizing cancer cells to TRAIL-induced death by micellar delivery of mitoxantrone. ( Grandhi, TS; Johnson, RH; Meldrum, DR; Potta, T; Rege, K; Taylor, DJ; Tian, Y, 2014)
"At various times after injection, tumors and samples of heart, kidney, liver and brain were excised."	1.39	Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues. ( Patel, KJ; Tannock, IF; Trédan, O, 2013)
"mitoxantrone) on human cancer cell lines (e."	1.38	Real-time cell analysis of human cancer cell lines after chemotherapy with functionalized magnetic nanoparticles. ( Alexiou, C; Dürr, S; Herrmann, M; Janko, C; Lyer, S; Mann, J; Schreiber, E; Tietze, R, 2012)
" The pharmacokinetic study in rats showed that LPG significantly prolonged the circulation time and enhanced the bioavailability of MX."	1.38	Dual-functional liposome for tumor targeting and overcoming multidrug resistance in hepatocellular carcinoma cells. ( Fan, R; Gan, Y; Guo, S; Li, F; Yu, M; Zhang, X; Zhu, C, 2012)
"Acquired resistance of cancer cells to various chemotherapeutic agents is known as multidrug resistance, and remains a critical factor in the success of cancer treatment."	1.38	Effects of α-adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and transport. ( Matsubara, M; Minegaki, T; Okumura, K; Takahashi, M; Takara, K; Yamamoto, K; Yokoyama, T, 2012)
"Multidrug resistance (MDR) in cancer is a phenomenon in which administration of a single chemotherapeutic agent causes cross-resistance of cancer cells to a variety of therapies even with different mechanisms of action."	1.37	Structure-activity relationship and molecular mechanisms of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and its analogues. ( Beck, WT; Bleeker, NP; Das, SG; Doshi, JM; Hermanson, DL; Srinivasan, B; Tang, R; Xing, C, 2011)
"We selected breast, ovarian and colon cancer cells (MCF-7, IGROV-1 and S-1) after exposure to 14 or 21 nM doxorubicin for only 10 days."	1.35	Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. ( Ambudkar, SV; Bates, SE; Calcagno, AM; Caplen, NJ; Chewning, KJ; Fostel, JM; Martin, SE; Salcido, CD; To, KK; Varticovski, L; Wu, CP, 2008)
"The relative increased risk of breast cancer in MS women under IS treatment warrants further attention."	1.35	Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. ( Berthier, F; Clavelou, P; Danzon, A; de Seze, J; Debouverie, M; Defer, G; Gout, O; Lebrun, C; Rumbach, L; Vermersch, P; Wiertlevski, S, 2008)
"When mitoxantrone-treated B16-F1 cells were used as antigen to inoculate mice, the mice acquired an ability to suppress proliferation of homologous tumor cells."	1.35	Mitoxantrone-mediated apoptotic B16-F1 cells induce specific anti-tumor immune response. ( Cao, C; Han, Y; Ren, Y; Wang, Y, 2009)
"Chemotherapy can induce anticancer immune responses."	1.35	Chemotherapy induces ATP release from tumor cells. ( Kepp, O; Kroemer, G; Martins, I; Métivier, D; Michaud, M; Perfettini, JL; Schlemmer, F; Senovilla, L; Séror, C; Tesniere, A; Zitvogel, L, 2009)
"Therefore, the fact that tumors do not develop in the majority of the population during their lifetime indicates the existence of other defense system(s)."	1.35	Experimental evidence for killing the resistant cells and raising the efficacy and decreasing the toxicity of cytostatics and irradiation by mixtures of the agents of the passive antitumor defense system in the case of various tumor and normal cell lines ( Kulcsár, G, 2009)
"AQ4N is a prodrug activated under hypoxic conditions to AQ4, which is structurally similar to mitoxantrone and inhibits topoisomerase II."	1.35	The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. ( Garbens, AB; Lalani, AS; Tannock, IF; Trédan, O, 2009)
"Mitoxantrone was encapsulated into pegylated SUVs using ammonium sulfate gradient method."	1.35	Lipid composition and grafted PEG affect in vivo activity of liposomal mitoxantrone. ( Cui, J; Guo, W; Li, C; Li, Y; Wang, C; Wang, J; Wang, Y; Zhang, L, 2008)
"These findings may be useful for cancer combinational therapy with erlotinib in the clinic."	1.34	Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. ( Ambudkar, SV; Ashby, CR; Bates, SE; Chen, ZS; Fu, LW; Kim, IW; Peng, XX; Robey, RW; Shen, T; Shi, Z; Shukla, S; Si, QS, 2007)
"Sensitivity of cancer cells to the cytotoxic effects of topoisomerase II targeting agents is thought to depend on the expression of the topoisomerase IIalpha isoform, and drug resistance is often associated with loss or mutation of topoisomerase IIalpha."	1.33	Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. ( Bicaku, E; Daud, AI; Marchion, DC; Munster, PN; Sullivan, DM; Turner, JG, 2005)
"Successful cancer gene therapy depends on the development of non-toxic, efficient, tumor cell- specific systemic gene delivery systems."	1.32	Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. ( Chang, EH; Ertem, G; Huang, W; Pirollo, KF; Rait, A; Xiang, L; Yu, B; Yu, W; Zhou, Q, 2004)
" Although the primary purpose of this study was to determine a clinically useful dosage and to characterize the toxicoses associated with mitoxantrone administration, each cat was monitored for response to treatment."	1.29	Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors. ( Atwater, SW; Ciekot, PE; Elmslie, RE; Klein, MK; Moore, AS; Obradovich, JE; Ogilvie, GK; Salmon, MD; Straw, RC; Vail, DM, 1993)
"Phase I and pharmacokinetic studies were performed in order to evaluate the maximum tolerated dose and the efficiency of 120 h continuous venous infusion (CVI) of mitoxantrone."	1.28	Phase I/II pharmacokinetic study of mitoxantrone by continuous venous infusion in patients with solid tumours and lymphoproliferative diseases. ( Bugat, R; Canal, P; Chevreau, C; de Forni, M; Huguet, F; Lachau, S; Laurent, G; Roche, H, 1991)
"Mitoxantrone is an anthracene derivative that acts as a cytostatic in a variety of cancers."	1.28	Novel assay method for mitoxantrone in plasma, and its application in cancer patients. ( Chang, SP; Chen, KY; Hu, OY; Law, CK; Song, YB, 1990)
" These results are of particular interest in clinical routines to calculate dosage regimens by Bayesian estimation methods."	1.28	Population pharmacokinetics of mitoxantrone performed by a NONMEM method. ( Iliadis, A; Launay, MC; Richard, B, 1989)
" Pharmacokinetic studies were performed by high-performance liquid chromatography (HPLC) with ultraviolet (UV) detection."	1.28	A phase I pharmacokinetic study of 21-day continuous infusion mitoxantrone. ( de Vries, EG; Greidanus, J; Mulder, NH; Oosterhuis, B; Sleijfer, DT; Uges, DR; Willemse, PH, 1989)
"Mitoxantrone is a synthetic anthraquinone that was developed through the doxorubicin analog program in hopes of retaining anticancer activity with less cardiotoxicity."	1.27	Cardiac evaluation of mitoxantrone. ( Balcerzak, SP; Bashore, TA; Neidhart, JA; Unverferth, BJ; Unverferth, DV, 1983)
"Mitoxantrone (DAD) is a new agent which intercalates into DNA."	1.27	Phase I trial of mitoxantrone by 24-hour continuous infusion. ( Anderson, KC; Canellos, GP; Cohen, GI; Frei, E; Garnick, MB; Israel, M; Meshad, MW; Modest, E; Pegg, WJ, 1983)
"Sixty-nine of 136 tumors plated for the TMQ study and 84 of 228 tumors plated for the ametantrone study were evaluable for drug-sensitivity assays."	1.27	Use of a human tumor cloning system to evaluate analogs of methotrexate and mitoxantrone. ( Elslager, E; Lathan, B; Von Hoff, DD, 1984)
"Mitoxantrone is an anthracenedione, showing structural similarities to doxorubicin."	1.27	An EORTC phase II study of mitoxantrone in solid tumors and lymphomas. ( Armand, JP; Bastit, P; Cappelaere, P; De Jager, R; Earl, H; Fargeot, P; Keiling, R; Renard, J; Rubens, R; van Glabbeke, M, 1984)
"Since 1970, we have carried out cancer chemotherapy and immunotherapy in cooperation with Japanese scientists, particularly Prof."	1.27	[Japanese-French cooperation in tumor pharmacotherapy: 1970-1990]. ( Mathé, G, 1983)
"Thus, the fresh human tumors and P-388 leukemia cells in vitro were better predictors than the established cell lines for the activity of these anthracene compounds in vivo against mouse tumors."	1.27	New antitumor agents containing the anthracene nucleus. ( Alberts, DS; Dorr, RT; Einspahr, J; Milton, S; Remers, WA; Tunget, CL; Wunz, TP, 1987)
" A dosage of 18 mg/m2 was administered as a short intravenous infusion every 3 weeks."	1.27	Novantrone for childhood malignant solid tumors. A pediatric oncology group phase II study. ( Etcubanas, E; Krance, RA; Mahoney, DH; Patterson, RB; Pratt, CB; Sexauer, C; Vietti, TJ, 1986)
" The pharmacokinetic parameters were also defined in five patients who were treated with combination chemotherapy (mitoxantrone 12 mg/m2, methotrexate 30 mg/m2 and vincristine 2 mg)."	1.27	Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. ( de Planque, MM; Deneve, W; McVie, JG; Schoemaker, TJ; Smith, IE; Van Belle, SJ; van Oosterom, AT, 1986)
"Mitoxantrone was readily detectable in tissues from all patients."	1.27	Human autopsy tissue concentrations of mitoxantrone. ( Green, RM; Maroun, JA; Mikhael, NZ; Montpetit, V; Stewart, DJ; Thibault, M, 1986)
"Mitoxantrone (NSC-301739) is a synthetic amino anthraquinone DNA intercalater active in several experimental tumor systems."	1.27	Phase I study of mitoxantrone on a daily X 5 schedule. ( Goldsmith, MA; Greenspan, EM; Holland, JF; Jaffrey, IH; Ohnuma, T, 1984)
" These data provide a pharmacological rationale for use of mitoxantrone on an intermittent dosing schedule."	1.27	Disposition of mitoxantrone in cancer patients. ( Alberts, DS; Davis, TP; Leigh, S; Peng, YM; Woodward, DL, 1985)
"The anticancer activity of ametantrone was investigated in a human tumor cloning assay."	1.27	Phase II study of ametantrone in a human tumor cloning assay. ( Crespeigne, N; Kenis, Y; Klastersky, J; Rombaut, W; Rozencweig, M; Sanders, C, 1985)
"Leukopenia was the dose-limiting toxic effect and thrombocytopenia was mild."	1.26	Clinical and clinical pharmacologic studies of mitoxantrone. ( Krakoff, IH; McCormack, JJ; Stewart, JA, 1982)
"Mitoxantrone appears to be a well-tolerated and clinically active agent against advanced breast carcinoma."	1.26	Mitoxantrone: a phase II study in the treatment of patients with advanced breast carcinoma and other solid tumours. ( Smith, IE; Stuart-Harris, RC, 1982)
"Mitoxantrone treatment induced two partial remissions (patients with metastatic squamous cell carcinomas of the hypopharynx and rectum) and one mixed response (patient with gastric carcinoma)."	1.26	Phase I clinical trial f mitoxantrone: a new anthracenedione anticancer drug. ( Alberts, DS; Goodman, GE; Griffith, KS; Herman, TS; Murray, E, 1980)

Timeframe	Studies, this research(%)	All Research%
pre-1990	57 (32.39)	18.7374
1990's	31 (17.61)	18.2507
2000's	27 (15.34)	29.6817
2010's	48 (27.27)	24.3611
2020's	13 (7.39)	2.80

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase I and Pharmacokinetic Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Solid Tumor[NCT02043756]	Phase 1	20 participants (Actual)	Interventional	2011-08-31	Completed
A Randomized Phase 1-2 Study of PLM60 in Patients With Peripheral T-Cell Lymphoma[NCT03553914]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2021-01-31	Withdrawn (stopped due to IND Inactive Status)
Phase I Trial of High-dose Topotecan in Association With Carboplatin, With Peripheral Blood Stem Cell Support in Patients With First Relapsed Ovarian Carcinoma Without Platinum-treatment Since 6-12 Months[NCT01177501]	Phase 1	3 participants (Actual)	Interventional	2009-04-30	Terminated (stopped due to choice of the principal investigator)
Adjuvant Dose-dense Sequential Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel or Weekly Paclitaxel in Patients With Resected High-risk Breast Cancer: A Hellenic Cooperative Oncology Group (HeCOG) Study[NCT04829890]		89 participants (Actual)	Observational	2004-02-29	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annual review of pharmacology and toxicology, 2000, Volume: 40 Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia;	2000
Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group. The Lancet. Oncology, 2023, Volume: 24, Issue:3 Topics: Adolescent; Antibiotics, Antineoplastic; Cardiomyopathies; Child; Humans; Mitoxantrone; Neoplasms; S	2023
Acute and early-onset cardiotoxicity in children and adolescents with cancer: a systematic review. BMC cancer, 2023, Sep-14, Volume: 23, Issue:1 Topics: Adolescent; Anthracyclines; Cardiotoxicity; Child; Heart; Humans; Mitoxantrone; Neoplasms; Polyketid	2023
Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics. Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2009, Volume: 14 Suppl 1 Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycy	2009
Preclinical models in electrochemotherapy: the role of veterinary patients. Future oncology (London, England), 2012, Volume: 8, Issue:7 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma	2012
[The multidrug tumor cell resistance phenotype caused by the impaired cell death program]. Vestnik Rossiiskoi akademii meditsinskikh nauk, 2004, Issue:12 Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Disease Progres	2004
Anthracyclines. Cancer chemotherapy and biological response modifiers, 2005, Volume: 22 Topics: Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Humans; Mitoxantrone; Neoplasms	2005
Curcumin as chemosensitizer. Advances in experimental medicine and biology, 2007, Volume: 595 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette T	2007
Pulmonary complications of novel antineoplastic agents for solid tumors. Chest, 2008, Volume: 133, Issue:2 Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetaboli	2008
[Recent developments in chemotherapy of malignant diseases]. Wiener klinische Wochenschrift, 1982, Dec-10, Volume: 94, Issue:23 Topics: Anthraquinones; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy	1982
Cardiotoxicity of chemotherapy. Current opinion in oncology, 1994, Volume: 6, Issue:4 Topics: Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combi	1994
Etoposide: four decades of development of a topoisomerase II inhibitor. European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:10 Topics: Administration, Oral; Anthracyclines; Antineoplastic Agents, Phytogenic; Etoposide; Humans; Mitoxant	1998
DNA topoisomerase II inhibitors. IARC monographs on the evaluation of carcinogenic risks to humans, 2000, Volume: 76 Topics: Amsacrine; Antineoplastic Agents; Carcinogens; Disease Models, Animal; Etoposide; Evidence-Based Med	2000
Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs, 1991, Volume: 41, Issue:3 Topics: Animals; Humans; Mitoxantrone; Neoplasms; Neoplasms, Experimental	1991
An overview of mitozantrone. The British journal of clinical practice, 1991,Autumn, Volume: 45, Issue:3 Topics: Acute Disease; Breast Neoplasms; Female; Humans; Leukemia; Mitoxantrone; Neoplasms	1991
Mitoxantrone: potential for use in intensive therapy. Seminars in oncology, 1990, Volume: 17, Issue:1 Suppl 3 Topics: Animals; Bone Marrow; Dose-Response Relationship, Drug; Humans; Mitoxantrone; Neoplasms	1990
Mitoxantrone: its development and role in clinical practice. Oncology (Williston Park, N.Y.), 1989, Volume: 3, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Humans; Mitoxantro	1989
Mitoxantrone: a novel anthracycline derivative. Clinical pharmacy, 1988, Volume: 7, Issue:8 Topics: Animals; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; Humans; Leukemia; Lymphoma; Mi	1988
Continuous infusion of low-dose doxorubicin, epirubicin and mitoxantrone in cancer chemotherapy: a review. Pharmaceutisch weekblad. Scientific edition, 1988, Dec-09, Volume: 10, Issue:6 Topics: Doxorubicin; Epirubicin; Humans; Infusions, Intravenous; Mitoxantrone; Neoplasms	1988
Chemotherapy of malignant disease: an update. Comprehensive therapy, 1988, Volume: 14, Issue:5 Topics: Amsacrine; Antineoplastic Agents; Cisplatin; Coformycin; Etoposide; Female; Humans; Ifosfamide; Male	1988
Mitoxantrone. Drug intelligence & clinical pharmacy, 1986, Volume: 20, Issue:2 Topics: Anthraquinones; Antibiotics, Antineoplastic; Breast Neoplasms; Humans; Kinetics; Lymphoma; Mitoxantr	1986
Mitoxantrone: a new anticancer drug with significant clinical activity. Annals of internal medicine, 1986, Volume: 105, Issue:1 Topics: Adult; Animals; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Child; Clinical Trials as T	1986
[Current status of clinical results of new antitumor drugs]. Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:2 Topics: Aminoacridines; Amsacrine; Anthracyclines; Anthraquinones; Antibiotics, Antineoplastic; Antineoplast	1985

Article	Year
Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy. Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule;	2014
Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy. Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule;	2014
Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy. Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule;	2014
Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy. Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule;	2014
A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brea	2011
Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients. Haematologica, 2011, Volume: 96, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Incidence; Inflam	2011
Clinical safety and tolerance of mitoxantrone. Seminars in oncology, 1984, Volume: 11, Issue:3 Suppl 1 Topics: Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow;	1984
[Phase II study of mitoxantrone]. Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:8 Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Human	1984
Management of peritoneal effusions with intracavitary mitoxantrone or bleomycin. Anti-cancer drugs, 1994, Volume: 5, Issue:3 Topics: Adult; Aged; Ascitic Fluid; Bleomycin; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Mit	1994
Delayed commencement of granulocyte colony-stimulating factor following autologous bone marrow transplantation accelerates neutrophil recovery and is cost-effective. Leukemia & lymphoma, 1994, Volume: 16, Issue:1-2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Com	1994
Toxicoses associated with the administration of mitoxantrone to dogs with malignant tumors: a dose escalation study. Journal of the American Veterinary Medical Association, 1994, Aug-15, Volume: 205, Issue:4 Topics: Animals; Bone Marrow; Diarrhea; Dog Diseases; Dogs; Female; Follow-Up Studies; Leukocyte Count; Logi	1994
Phase I trial of mitoxantrone and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid malignancies. Investigational new drugs, 1993, Volume: 11, Issue:4 Topics: Adult; Aged; Drug Administration Schedule; Drug Tolerance; Female; Granulocyte-Macrophage Colony-Sti	1993
Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplanta	1994
Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support. Cancer, 1996, Jun-01, Volume: 77, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Granulocyte-Macrophage Colony-S	1996
A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors. Investigational new drugs, 1998, Volume: 16, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male	1998
High-dose chemotherapy combined with escalating doses of cyclosporin A and an autologous bone marrow transplant for the treatment of drug-resistant solid tumors: a phase I clinical trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 1995, Volume: 1, Issue:12 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bone Marrow Transplantation; Carb	1995
Myeloprotective effect of a non-toxic indigenous preparation Rasayana in cancer patients receiving chemotherapy and radiation therapy. A pilot study. Journal of experimental & clinical cancer research : CR, 1999, Volume: 18, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Bone Marrow; Chemotherapy, Adjuvant; C	1999
Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours. Cancer chemotherapy and pharmacology, 2001, Volume: 47, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura	2001
High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: a phase I trial. Bone marrow transplantation, 2001, Volume: 27, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Granulocyte Col	2001
Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation. British journal of cancer, 1992, Volume: 65, Issue:3 Topics: Adolescent; Adult; Bone Marrow Transplantation; Chromatography, High Pressure Liquid; Female; Humans	1992
Intrapleural palliative treatment of malignant pleural effusions with mitoxantrone versus placebo (pleural tube alone). Annals of oncology : official journal of the European Society for Medical Oncology, 1991, Volume: 2, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Mitoxantrone; Neoplasms; Palliati	1991
Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumors. Investigational new drugs, 1991, Volume: 9, Issue:3 Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relation	1991
A phase I trial of 14-day continuous intravenous infusion mitoxantrone. Anti-cancer drugs, 1991, Volume: 2, Issue:3 Topics: Adult; Aged; Diarrhea; Drug Evaluation; Female; Gastrointestinal Diseases; Humans; Infusions, Intrav	1991
A phase I-II study of high-dose cyclophosphamide, thiotepa and escalating doses of mitoxantrone with autologous stem cell rescue in patients with refractory malignancies. Bone marrow transplantation, 1990, Volume: 6, Issue:6 Topics: Actuarial Analysis; Chicago; Cyclophosphamide; Drug Evaluation; Heart Failure; Hematopoietic Stem Ce	1990
Intracavitary chemotherapy. Current problems in cancer, 1986, Volume: 10, Issue:8 Topics: Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Ca	1986
Hyperalimentation in autologous bone marrow transplantation for solid tumors. Comparison of total parenteral versus partial parenteral plus enteral nutrition. Cancer, 1989, Nov-15, Volume: 64, Issue:10 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Marrow Transplantation; Com	1989
Mitoxantrone: a novel anthracycline derivative. Clinical pharmacy, 1988, Volume: 7, Issue:8 Topics: Animals; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; Humans; Leukemia; Lymphoma; Mi	1988
Treatment evaluation in active control studies. Cancer treatment reports, 1987, Volume: 71, Issue:11 Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Diagnosis-Related Groups; Doxorub	1987
Mitoxantrone: a new anticancer drug with significant clinical activity. Annals of internal medicine, 1986, Volume: 105, Issue:1 Topics: Adult; Animals; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Child; Clinical Trials as T	1986
Papers presented at a symposium on cancer chemotherapy in the 1980's. Monte Carlo, 11th-12th October, 1984. Investigational new drugs, 1985, Volume: 3, Issue:2 Topics: Anthraquinones; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation; Humans; Mitoxantro	1985

Article	Year
Chemical genetics reveals a complex functional ground state of neural stem cells. Nature chemical biology, 2007, Volume: 3, Issue:5 Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic	2007
The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds. Bioorganic & medicinal chemistry, 2008, Apr-01, Volume: 16, Issue:7 Topics: Anthracyclines; Antigens, Neoplasm; Antineoplastic Agents; Cell Line; Cell Survival; DNA; DNA Topois	2008
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and its analogues. Journal of medicinal chemistry, 2011, Aug-25, Volume: 54, Issue:16 Topics: Antineoplastic Agents; Benzopyrans; Cell Line, Tumor; Cell Survival; Daunorubicin; Drug Resistance,	2011
Design, synthesis and evaluation of telomerase inhibitory, hTERT repressing, and anti-proliferation activities of symmetrical 1,8-disubstituted amidoanthraquinones. European journal of medicinal chemistry, 2012, Volume: 50 Topics: Alkaline Phosphatase; Anthraquinones; Apoptosis; Cell Proliferation; Drug Design; Enzyme Inhibitors;	2012
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents. Journal of medicinal chemistry, 2015, Aug-13, Volume: 58, Issue:15 Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Neoplasms; Noscap	2015
A Nanoplatform to Amplify Apoptosis-to-Pyroptosis Immunotherapy via Immunomodulation of Myeloid-Derived Suppressor Cells. ACS applied materials & interfaces, 2021, Oct-13, Volume: 13, Issue:40 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Carriers; Drug Liberation; Female;	2021
Blockage of the IDO1 pathway by charge-switchable nanoparticles amplifies immunogenic cell death for enhanced cancer immunotherapy. Acta biomaterialia, 2022, 09-15, Volume: 150 Topics: Cell Line, Tumor; Immunogenic Cell Death; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mitox	2022
In Silico Identification and In Vitro Evaluation of New ABCG2 Transporter Inhibitors as Potential Anticancer Agents. International journal of molecular sciences, 2022, Dec-31, Volume: 24, Issue:1 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Dr	2022
Cancer-cell-membrane-camouflaged supramolecular self-assembly of antisense oligonucleotide and chemodrug for targeted combination therapy. Nanoscale, 2023, Jan-27, Volume: 15, Issue:4 Topics: Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Mitoxantrone; Neoplasms; Oligonucleoti	2023
Delivery of quercetin for breast cancer and targeting potentiation via hyaluronic nano-micelles. International journal of biological macromolecules, 2023, Jul-01, Volume: 242, Issue:Pt 2 Topics: Animals; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Drug Liberation; Hyaluronic Acid; M	2023
Enhanced pH-Responsive Chemo/Chemodynamic Synergistic Cancer Therapy Based on In Situ Cu ACS applied bio materials, 2023, 08-21, Volume: 6, Issue:8 Topics: Animals; Copper; Hydrogen-Ion Concentration; Mice; Mitoxantrone; Neoplasms; Tumor Microenvironment	2023
Rational Design, Synthesis and Binding Affinity Studies of Anthraquinone Derivatives Conjugated to Gonadotropin-Releasing Hormone (GnRH) Analogues towards Selective Immunosuppression of Hormone-Dependent Cancer. International journal of molecular sciences, 2023, Oct-16, Volume: 24, Issue:20 Topics: Antineoplastic Agents; Gonadotropin-Releasing Hormone; Humans; Immunologic Factors; Immunosuppressio	2023
Development of Novel Epigenetic Anti-Cancer Therapy Targeting TET Proteins. International journal of molecular sciences, 2023, Nov-15, Volume: 24, Issue:22 Topics: 5-Methylcytosine; Animals; Dioxygenases; DNA Methylation; DNA-Binding Proteins; Epigenesis, Genetic;	2023
Biphasic Increases of Cell Surface Calreticulin Following Treatment with Mitoxantrone. Biological & pharmaceutical bulletin, 2020, Oct-01, Volume: 43, Issue:10 Topics: Antineoplastic Agents; Apoptosis; Calnexin; Calreticulin; Cell Membrane; Endoplasmic Reticulum; Endo	2020
Liposomal Delivery of Mitoxantrone and a Cholesteryl Indoximod Prodrug Provides Effective Chemo-immunotherapy in Multiple Solid Tumors. ACS nano, 2020, 10-27, Volume: 14, Issue:10 Topics: Animals; Cell Line, Tumor; Immunotherapy; Liposomes; Mice; Mitoxantrone; Neoplasms; Prodrugs; Trypto	2020
Selective killing of homologous recombination-deficient cancer cell lines by inhibitors of the RPA:RAD52 protein-protein interaction. PloS one, 2021, Volume: 16, Issue:3 Topics: Apoptosis; BRCA1 Protein; Cell Death; Cell Line, Tumor; Cell Survival; DNA Damage; DNA Repair; Doxor	2021
DNA Damage Induces a Secretory Program in the Quiescent TME that Fosters Adverse Cancer Phenotypes. Molecular cancer research : MCR, 2017, Volume: 15, Issue:7 Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA Damage; Fibroblasts; Humans; Interleukin-1beta;	2017
Hyaluronic acid/polyethylene glycol nanoparticles for controlled delivery of mitoxantrone. Artificial cells, nanomedicine, and biotechnology, 2018, Volume: 46, Issue:3 Topics: Delayed-Action Preparations; Humans; Hyaluronan Receptors; Hyaluronic Acid; Hydrogen Bonding; MCF-7	2018
Surface PEGylation of Mesoporous Silica Nanorods (MSNR): Effect on loading, release, and delivery of mitoxantrone in hypoxic cancer cells. Scientific reports, 2017, 05-23, Volume: 7, Issue:1 Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Drug Delivery Systems	2017
Pituitary adenylate cyclase-activating polypeptide (PACAP) protects against mitoxantrone-induced cardiac injury in mice. Peptides, 2017, Volume: 95 Topics: Animals; Cardiotoxicity; Cell Line, Tumor; Disease Models, Animal; Heart Injuries; Humans; Mice; Mit	2017
ABC-transporter blockage mediated by xanthotoxin and bergapten is the major pathway for chemosensitization of multidrug-resistant cancer cells. Toxicology and applied pharmacology, 2017, 12-15, Volume: 337 Topics: 5-Methoxypsoralen; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B;	2017
Physalis Mottle Virus-Like Particles as Nanocarriers for Imaging Reagents and Drugs. Biomacromolecules, 2017, Dec-11, Volume: 18, Issue:12 Topics: Animals; Cell Line; Cell Line, Tumor; Doxorubicin; Drug Carriers; HeLa Cells; Humans; Indicators and	2017
Facile Supramolecular Approach to Nucleic-Acid-Driven Activatable Nanotheranostics That Overcome Drawbacks of Photodynamic Therapy. ACS nano, 2018, 01-23, Volume: 12, Issue:1 Topics: Animals; Antineoplastic Agents; Delayed-Action Preparations; Humans; Indoles; Isoindoles; Male; MCF-	2018
eIF2α phosphorylation is pathognomonic for immunogenic cell death. Cell death and differentiation, 2018, Volume: 25, Issue:8 Topics: Activating Transcription Factor 4; Activating Transcription Factor 6; Algorithms; Animals; Antineopl	2018
PEGylated graphene oxide/Fe3O4 nanocomposite: Synthesis, characterization, and evaluation of its performance as de novo drug delivery nanosystem. Bio-medical materials and engineering, 2018, Volume: 29, Issue:2 Topics: Antineoplastic Agents; Cell Line; Cell Survival; Delayed-Action Preparations; Drug Delivery Systems;	2018
Targeting of drug-loaded nanoparticles to tumor sites increases cell death and release of danger signals. Journal of controlled release : official journal of the Controlled Release Society, 2018, 09-10, Volume: 285 Topics: Alarmins; Antineoplastic Agents; Cell Death; Cell Proliferation; Drug Delivery Systems; Equipment De	2018
Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells. Cancer letters, 2019, Volume: 440-441 Topics: Adenosine Triphosphatases; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic	2019
Mitoxantrone-Loaded PEGylated Gold Nanocomplexes for Cancer Therapy. Journal of nanoscience and nanotechnology, 2019, 02-01, Volume: 19, Issue:2 Topics: Gold; HeLa Cells; Humans; Metal Nanoparticles; Mitoxantrone; Neoplasms; Polyethylene Glycols	2019
A surfactant-like chemotherapeutic agent as a nanocarrier for delivering photosensitizers against cancer: A facile drug-delivering-drug strategy. International journal of pharmaceutics, 2019, May-01, Volume: 562 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chlorophyll; Drug Carriers; Drug Delivery Systems;	2019
pH/near infrared dual-triggered drug delivery system based black phosphorus nanosheets for targeted cancer chemo-photothermal therapy. Colloids and surfaces. B, Biointerfaces, 2019, Aug-01, Volume: 180 Topics: Animals; Antineoplastic Agents; Drug Delivery Systems; Drug Liberation; Female; Hyaluronic Acid; Hyd	2019
Stimuli-Responsive Polymer-Prodrug Hybrid Nanoplatform for Multistage siRNA Delivery and Combination Cancer Therapy. Nano letters, 2019, 09-11, Volume: 19, Issue:9 Topics: Cell Line, Tumor; Drug Delivery Systems; Gene Transfer Techniques; Humans; Hydrophobic and Hydrophil	2019
Efficient drug-delivery using magnetic nanoparticles--biodistribution and therapeutic effects in tumour bearing rabbits. Nanomedicine : nanotechnology, biology, and medicine, 2013, Volume: 9, Issue:7 Topics: Animals; Drug Delivery Systems; Female; Magnetite Nanoparticles; Mitoxantrone; Neoplasms; Particle S	2013
Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues. Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:1 Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Coronary Vessels; Dox	2013
Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. Cell death and differentiation, 2014, Volume: 21, Issue:1 Topics: Animals; Antineoplastic Agents; Apoptosis; Calreticulin; Cell Line, Tumor; Chemokine CXCL2; Dendriti	2014
Sensitizing cancer cells to TRAIL-induced death by micellar delivery of mitoxantrone. Nanomedicine (London, England), 2014, Volume: 9, Issue:12 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Drug Stability; Dr	2014
Plasma stable, pH-sensitive fusogenic polymer-modified liposomes: A promising carrier for mitoxantrone. Journal of biomaterials applications, 2014, Volume: 29, Issue:1 Topics: Antineoplastic Agents; Biocompatible Materials; Cell Line, Tumor; Cell Proliferation; Drug Carriers;	2014
Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disorders. American journal of hematology, 2014, Volume: 89, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Chromosome Breakpoints; Chromosomes, Human, Pair 15; Chromosomes	2014
Interaction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro. BMC complementary and alternative medicine, 2014, Jan-08, Volume: 14 Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cytostatic Agents; Deoxycytidine; Doceta	2014
Novel ametantrone-amsacrine related hybrids as topoisomerase IIβ poisons and cytotoxic agents. Archiv der Pharmazie, 2014, Volume: 347, Issue:10 Topics: Amsacrine; Cell Proliferation; Cell Survival; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins	2014
Inhibition of c-Abl kinase activity renders cancer cells highly sensitive to mitoxantrone. PloS one, 2014, Volume: 9, Issue:8 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Caspase 7; Cell Line, Tumor; DNA Damage; Do	2014
Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal. Oncotarget, 2015, Sep-29, Volume: 6, Issue:29 Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Calreticulin; Cancer Vacc	2015
Pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells. Cancer letters, 2016, 06-28, Volume: 376, Issue:1 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Binding Sites; Cell	2016
Inhibition of DNA Topoisomerase Type IIα (TOP2A) by Mitoxantrone and Its Halogenated Derivatives: A Combined Density Functional and Molecular Docking Study. BioMed research international, 2016, Volume: 2016 Topics: Antigens, Neoplasm; Binding Sites; DNA Topoisomerases, Type II; DNA-Binding Proteins; Halogenation;	2016
Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study. Neurology, 2016, Jun-07, Volume: 86, Issue:23 Topics: Adolescent; Adult; Aged; Female; Follow-Up Studies; Germany; Humans; Immunosuppressive Agents; Incid	2016
Anthracycline Drugs on Modified Surface of Quercetin-Loaded Polymer Nanoparticles: A Dual Drug Delivery Model for Cancer Treatment. PloS one, 2016, Volume: 11, Issue:5 Topics: Anthracyclines; Antibiotics, Antineoplastic; Biopolymers; Calorimetry, Differential Scanning; Doxoru	2016
Myeloperoxidase Enhances Etoposide and Mitoxantrone-Mediated DNA Damage: A Target for Myeloprotection in Cancer Chemotherapy. Molecular pharmacology, 2017, Volume: 91, Issue:1 Topics: Antigens, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Cytoprotection; DNA; DNA Damage; DNA To	2017
Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib. Pharmacological research, 2017, Volume: 119 Topics: Anilides; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line,	2017
Lipid composition and grafted PEG affect in vivo activity of liposomal mitoxantrone. International journal of pharmaceutics, 2008, Oct-01, Volume: 362, Issue:1-2 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Compounding; Drug Screening Assays, Antitumor	2008
The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. Cancer research, 2009, Feb-01, Volume: 69, Issue:3 Topics: Animals; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Cell Hypoxia; Humans; Male;	2009
Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins. Molecular cancer therapeutics, 2009, Volume: 8, Issue:3 Topics: Adaptation, Physiological; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Mem	2009
Experimental evidence for killing the resistant cells and raising the efficacy and decreasing the toxicity of cytostatics and irradiation by mixtures of the agents of the passive antitumor defense system in the case of various tumor and normal cell lines Cancer biotherapy & radiopharmaceuticals, 2009, Volume: 24, Issue:1 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line	2009
Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL). Bioconjugate chemistry, 2009, Volume: 20, Issue:6 Topics: Antibodies; Biological Transport; Cell Line, Tumor; Cysteine; ErbB Receptors; Gene Expression Regula	2009
A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy. PloS one, 2009, May-24, Volume: 4, Issue:5 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP Binding Cassette	2009
Chemotherapy induces ATP release from tumor cells. Cell cycle (Georgetown, Tex.), 2009, Nov-15, Volume: 8, Issue:22 Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; Cadmium; Cell Line, Tumor; Cispla	2009
Mitoxantrone-mediated apoptotic B16-F1 cells induce specific anti-tumor immune response. Cellular & molecular immunology, 2009, Volume: 6, Issue:6 Topics: Animals; Apoptosis; Calreticulin; Cell Line, Tumor; Cell Membrane; Female; Male; Mice; Mice, Inbred	2009
Mitoxantrone is expelled by the ABCG2 multidrug transporter directly from the plasma membrane. Biochimica et biophysica acta, 2011, Volume: 1808, Issue:1 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette	2011
Dynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cells. PloS one, 2010, Dec-07, Volume: 5, Issue:12 Topics: Acetanilides; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Bi	2010
5,7-Dimethoxyflavone and multiple flavonoids in combination alter the ABCG2-mediated tissue distribution of mitoxantrone in mice. Pharmaceutical research, 2011, Volume: 28, Issue:5 Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding	2011
Use of baculovirus BacMam vectors for expression of ABC drug transporters in mammalian cells. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:2 Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette	2012
Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (New York, N.Y.), 2011, Dec-16, Volume: 334, Issue:6062 Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Autophagy; Calreticulin; Cell Death; Cell Li	2011
Mitoxantrone targets the ATP-binding site of FAK, binds the FAK kinase domain and decreases FAK, Pyk-2, c-Src, and IGF-1R in vitro kinase activities. Anti-cancer agents in medicinal chemistry, 2013, Volume: 13, Issue:4 Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Binding Sites; Cell Survival	2013
Effects of α-adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and transport. PloS one, 2012, Volume: 7, Issue:2 Topics: Adrenergic alpha-1 Receptor Antagonists; Antineoplastic Agents; ATP Binding Cassette Transporter, Su	2012
Real-time cell analysis of human cancer cell lines after chemotherapy with functionalized magnetic nanoparticles. Anticancer research, 2012, Volume: 32, Issue:5 Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; L-Lactate Dehydrogen	2012
Dual-functional liposome for tumor targeting and overcoming multidrug resistance in hepatocellular carcinoma cells. Biomaterials, 2012, Volume: 33, Issue:29 Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Multiple; Humans; Liposomes;	2012
Specific targeting of cancer cells by multifunctional mitoxantrone-conjugated magnetic nanoparticles. Journal of drug targeting, 2013, Volume: 21, Issue:4 Topics: Cell Line, Tumor; Dopamine; Drug Delivery Systems; Ferric Compounds; Folic Acid Transporters; Humans	2013
Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. Nucleic acids research, 2004, Mar-16, Volume: 32, Issue:5 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; DNA; Gene Expression; G	2004
Immunity during monochemotherapy with mitoxantrone: preliminary results. Journal of chemotherapy (Florence, Italy), 1989, Volume: 1, Issue:4 Suppl Topics: Adjuvants, Immunologic; Anthraquinones; Antineoplastic Agents; Drug Hypersensitivity; Humans; Leukoc	1989
Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Dec-01, Volume: 11, Issue:23 Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Butyrates; Chromatin; DNA Topoisomerases, Type	2005
[Investigation on the properties of mitoxantrone-insulin conjugates lyophilized powder]. Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi, 2006, Volume: 23, Issue:1 Topics: Animals; Antimetabolites, Antineoplastic; Drug Carriers; Drug Delivery Systems; Drug Stability; Insu	2006
Combined effect of low-power laser irradiation and anthraquinone anticancer drug aclarubicin on survival of immortalized cells: Comparison with mitoxantrone. Cell biology international, 2006, Volume: 30, Issue:8 Topics: Aclarubicin; Animals; Antibiotics, Antineoplastic; Cell Line; Cell Survival; Lasers; Mice; Mitoxantr	2006
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer research, 2007, Nov-15, Volume: 67, Issue:22 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transport	2007
Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. British journal of cancer, 2008, May-06, Volume: 98, Issue:9 Topics: Acetylation; Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, S	2008
Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England), 2008, Volume: 14, Issue:3 Topics: Adult; Azathioprine; Breast Neoplasms; Central Nervous System Neoplasms; Cyclophosphamide; Digestive	2008
Mitozantrone. Lancet (London, England), 1984, Aug-04, Volume: 2, Issue:8397 Topics: Animals; Anthraquinones; Antineoplastic Agents; Child; Dogs; Female; Humans; Mitoxantrone; Neoplasms	1984
[Japanese-French cooperation in tumor pharmacotherapy: 1970-1990]. Gan to kagaku ryoho. Cancer & chemotherapy, 1983, Volume: 10, Issue:4 Pt 2 Topics: Aclarubicin; Animals; Anthraquinones; Antibiotics, Antineoplastic; Antineoplastic Agents; Cricetinae	1983
Use of a human tumor cloning system to evaluate analogs of methotrexate and mitoxantrone. Cancer treatment reports, 1984, Volume: 68, Issue:5 Topics: Anthraquinones; Antineoplastic Agents; Cell Line; Colony-Forming Units Assay; Drug Evaluation, Precl	1984
[Current clinical status of new anticancer drugs]. Gan no rinsho. Japan journal of cancer clinics, 1983, Volume: 29, Issue:10 Topics: Altretamine; Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;	1983
[Use of mitoxantrone in the treatment of tumors]. Casopis lekaru ceskych, 1984, Jul-13, Volume: 123, Issue:28 Topics: Anthraquinones; Antineoplastic Agents; Humans; Mitoxantrone; Neoplasms	1984
Phase I study of mitoxantrone on a daily X 5 schedule. American journal of clinical oncology, 1984, Volume: 7, Issue:5 Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Female; Humans; Leukopenia; Mal	1984
An EORTC phase II study of mitoxantrone in solid tumors and lymphomas. European journal of cancer & clinical oncology, 1984, Volume: 20, Issue:11 Topics: Adolescent; Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Carcinom	1984
Phase I investigation of ametantrone. Cancer treatment reports, 1983, Volume: 67, Issue:11 Topics: Aged; Anthraquinones; Arrhythmias, Cardiac; Bone Marrow; Dose-Response Relationship, Drug; Drug Eval	1983
Comparative cytotoxicity of adriamycin, mitoxantrone and bisantrene as measured by a human tumor cloning system. Investigational new drugs, 1983, Volume: 1, Issue:2 Topics: Anthracenes; Anthraquinones; Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Separation; Ce	1983
[Mitoxantrone HCl (1,4-dihydroxy-4, 8-bis[[2-(hydroxyethyl)-amino-ethyl)]amino 9,10-anthracenedione dihydrochloride (NSC 301739) - a new cytostatic]. Onkologie, 1980, Volume: 3, Issue:6 Topics: Animals; Anthracenes; Antineoplastic Agents; Dogs; Dose-Response Relationship, Drug; Drug Evaluation	1980
Cardiac evaluation of mitoxantrone. Cancer treatment reports, 1983, Volume: 67, Issue:4 Topics: Aged; Anthraquinones; Antineoplastic Agents; Biopsy; Female; Heart Failure; Heart Function Tests; Hu	1983
Phase I trial of mitoxantrone by 24-hour continuous infusion. Cancer treatment reports, 1983, Volume: 67, Issue:5 Topics: Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Agents; Child; Child, Preschool; Drug Evalua	1983
Current status of clinical trials of m-AMSA, dihydroxyanthracenedione, and deoxycoformycin. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1982, Volume: 80 Topics: Adenosine Deaminase Inhibitors; Aminoacridines; Amsacrine; Anthracenes; Antineoplastic Agents; Cofor	1982
Phase I study of a 5-day schedule of mitoxantrone (dihydroxyanthracenedione). Cancer treatment reports, 1982, Volume: 66, Issue:6 Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; H	1982
Clinical and clinical pharmacologic studies of mitoxantrone. Cancer treatment reports, 1982, Volume: 66, Issue:6 Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; F	1982
Pharmacology of mitoxantrone in cancer patients. Cancer chemotherapy and pharmacology, 1982, Volume: 8, Issue:1 Topics: Aged; Anthraquinones; Antineoplastic Agents; Bile; Female; Humans; Kidney; Kinetics; Liver; Liver Di	1982
Mitoxantrone: a phase II study in the treatment of patients with advanced breast carcinoma and other solid tumours. Cancer chemotherapy and pharmacology, 1982, Volume: 8, Issue:2 Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Dr	1982
Phase II trial of mitoxantrone. Cancer treatment reports, 1982, Volume: 66, Issue:11 Topics: Adult; Aged; Agranulocytosis; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Female; Heart;	1982
Phase I clinical trial with ametantrone (NSC-287513). European journal of cancer & clinical oncology, 1981, Volume: 17, Issue:7 Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Evaluatio	1981
Phase I clinical trial f mitoxantrone: a new anthracenedione anticancer drug. Cancer chemotherapy and pharmacology, 1980, Volume: 5, Issue:1 Topics: Aged; Anthracenes; Antineoplastic Agents; Drug Evaluation; Female; Humans; Leukopenia; Male; Middle	1980
Prolonged impairment of hematopoiesis after high-dose therapy followed by autologous bone marrow transplantation. Blood, 1995, Jun-01, Volume: 85, Issue:11 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transpla	1995
Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors. Journal of the American Veterinary Medical Association, 1993, Jun-01, Volume: 202, Issue:11 Topics: Animals; Anorexia; Carcinoma, Squamous Cell; Cat Diseases; Cats; Chemotherapy, Adjuvant; Dose-Respon	1993
[Percutaneous drainage of refractory necrotizing tumors: experience in 9 patients]. RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 1995, Volume: 163, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Cystadenocarcinoma; Drainage; Female; His	1995
Mobilized peripheral blood progenitor cells (PBPC) in support of tandem cycles of high-dose chemotherapy (HDC). Bone marrow transplantation, 1996, Volume: 18, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Trans	1996
Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nature biotechnology, 1999, Volume: 17, Issue:8 Topics: Animals; Antineoplastic Agents; Cell Line; Drug Carriers; Female; Humans; Liposomes; Mice; Mitoxantr	1999
Intrathecal mitozantrone has to be prohibited. Leukemia, 2000, Volume: 14, Issue:12 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Female; Humans; Injections,	2000
Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study. Journal of cancer research and clinical oncology, 1991, Volume: 117 Suppl 4 Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Admi	1991
Continuous infusion of chemotherapy on an outpatient basis via a totally implanted venous access port. European journal of cancer (Oxford, England : 1990), 1991, Volume: 27, Issue:2 Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Eval	1991
Phase I/II pharmacokinetic study of mitoxantrone by continuous venous infusion in patients with solid tumours and lymphoproliferative diseases. European journal of cancer (Oxford, England : 1990), 1991, Volume: 27, Issue:6 Topics: Adolescent; Adult; Aged; Drug Evaluation; Female; Hematologic Diseases; Humans; Infusions, Intraveno	1991
Toxicoses associated with administration of mitoxantrone to dogs with malignant tumors. Journal of the American Veterinary Medical Association, 1991, May-01, Volume: 198, Issue:9 Topics: Animals; Anorexia; Bone Marrow; Diarrhea; Dog Diseases; Dogs; Female; Lymphoma; Male; Mitoxantrone;	1991
Efficacy of mitoxantrone against various neoplasms in dogs. Journal of the American Veterinary Medical Association, 1991, May-01, Volume: 198, Issue:9 Topics: Animals; Carcinoma; Dog Diseases; Dogs; Lymphoma; Mitoxantrone; Neoplasms; Prospective Studies; Remi	1991
Novel assay method for mitoxantrone in plasma, and its application in cancer patients. Journal of chromatography, 1990, Nov-16, Volume: 532, Issue:2 Topics: Adsorption; Antineoplastic Agents; Chromatography, High Pressure Liquid; Drug Stability; Glass; Half	1990
Evaluation of intense renal parenchymal activity ("hot kidneys") on bone scintigraphy. Clinical nuclear medicine, 1990, Volume: 15, Issue:4 Topics: Adult; Bone and Bones; Calcitonin; Female; Humans; Hypercalcemia; Kidney; Male; Middle Aged; Mitoxan	1990
Use of in vitro dose response effects to select antineoplastics for high-dose or regional administration regimens. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:12 Topics: Antineoplastic Agents; Bleomycin; Cisplatin; Colony-Forming Units Assay; Dose-Response Relationship,	1986
New antitumor agents containing the anthracene nucleus. Journal of medicinal chemistry, 1987, Volume: 30, Issue:8 Topics: Animals; Anthracenes; Cell Line; Chemical Phenomena; Chemistry; DNA; Humans; Leukemia L1210; Leukemi	1987
High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors. Cancer research, 1989, Aug-15, Volume: 49, Issue:16 Topics: Adult; Bone Marrow Transplantation; Breast Neoplasms; Cyclophosphamide; Female; Humans; Male; Melpha	1989
Population pharmacokinetics of mitoxantrone performed by a NONMEM method. Journal of pharmaceutical sciences, 1989, Volume: 78, Issue:10 Topics: Chromatography, High Pressure Liquid; Half-Life; Humans; Infusions, Intravenous; Mitoxantrone; Model	1989
Laryngeal infiltration in chronic myelomonocytic leukaemia. Clinical and laboratory haematology, 1989, Volume: 11, Issue:4 Topics: Aged; Airway Obstruction; Dyspnea; Female; Granulocytes; Humans; Larynx; Leukemia, Myelomonocytic, C	1989
[Advances in intercalating drugs]. Pathologie-biologie, 1989, Volume: 37, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epirubicin; Humans; Intercalating Agent	1989
Mitoxantrone and high-dose ara-C in refractory malignancies: a phase I trial. Medical and pediatric oncology, 1989, Volume: 17, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Drug Evaluatio	1989
A phase I pharmacokinetic study of 21-day continuous infusion mitoxantrone. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:6 Topics: Adult; Aged; Drug Administration Schedule; Drug Evaluation; Female; Humans; Infusions, Intravenous;	1989
A method for the evaluation of dose-toxicity relationships in clinical trials. Statistics in medicine, 1989, Volume: 8, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials as Topic; Dose-Response Relat	1989
[Clinical study of acute cardiotoxicity of anti-cancer agents-- analysis using Holter ECG monitoring]. Gan to kagaku ryoho. Cancer & chemotherapy, 1988, Volume: 15, Issue:6 Topics: Adult; Aged; Doxorubicin; Electrocardiography; Epirubicin; Female; Heart; Heart Rate; Humans; Male;	1988
A phase II study of mitoxantrone. Tumori, 1988, Oct-31, Volume: 74, Issue:5 Topics: Adult; Aged; Bone Marrow; Drug Evaluation; Female; Heart; Humans; Male; Middle Aged; Mitoxantrone; N	1988
Evaluation of a totally implanted venous access port and portable pump in a continuous chemotherapy infusion schedule on an outpatient basis. European journal of cancer & clinical oncology, 1987, Volume: 23, Issue:11 Topics: Adult; Aged; Ambulatory Care; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;	1987
Novantrone for childhood malignant solid tumors. A pediatric oncology group phase II study. Investigational new drugs, 1986, Volume: 4, Issue:1 Topics: Adolescent; Adult; Anthraquinones; Antineoplastic Agents; Cardiomyopathies; Child; Child, Preschool;	1986
The clinical pharmacology of mitozantrone. Cancer chemotherapy and pharmacology, 1986, Volume: 17, Issue:2 Topics: Adult; Aged; Anthraquinones; Chromatography, High Pressure Liquid; Female; Humans; Male; Metabolic C	1986
Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. Cancer chemotherapy and pharmacology, 1986, Volume: 18, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Female;	1986
Mitozantrone. Drug and therapeutics bulletin, 1986, Sep-08, Volume: 24, Issue:18 Topics: Breast Neoplasms; Humans; Leukemia; Liver Neoplasms; Lymphoma; Mitoxantrone; Neoplasms	1986
Human autopsy tissue concentrations of mitoxantrone. Cancer treatment reports, 1986, Volume: 70, Issue:11 Topics: Autopsy; Chromatography, High Pressure Liquid; Humans; Kinetics; Mitoxantrone; Neoplasms; Tissue Dis	1986
Assessment of ventricular function by radionuclide angiography in patients receiving 4'-epidoxorubicin and mitoxantrone. Cancer chemotherapy and pharmacology, 1985, Volume: 15, Issue:3 Topics: Adolescent; Adult; Aged; Angiocardiography; Anthraquinones; Antibiotics, Antineoplastic; Antineoplas	1985
Disposition of mitoxantrone in cancer patients. Cancer research, 1985, Volume: 45, Issue:4 Topics: Anthraquinones; Antineoplastic Agents; Carbon Radioisotopes; Chromatography, High Pressure Liquid; F	1985
Comment on mitoxantrone. Drug intelligence & clinical pharmacy, 1985, Volume: 19, Issue:3 Topics: Animals; Anthraquinones; Antibiotics, Antineoplastic; Dogs; Doxorubicin; Heart Diseases; Humans; Mit	1985
[Mitoxantrone--a new cytostatic agent]. Fortschritte der Medizin, 1985, Feb-28, Volume: 103, Issue:8 Topics: Acute Disease; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Leukemia; Mi	1985
Phase II study of ametantrone in a human tumor cloning assay. European journal of cancer & clinical oncology, 1985, Volume: 21, Issue:2 Topics: Anthraquinones; Cell Survival; Doxorubicin; Drug Evaluation; Female; Humans; Mitoxantrone; Neoplasms	1985

mitoxantrone and Benign Neoplasms

Research Excerpts

Research

Studies (176)

Authors

Clinical Trials (4)

Trial Overview

Reviews

Trials

Other Studies

Authors	Studies
Tukey, RH	1
Strassburg, CP	1
Diamandis, P	1
Wildenhain, J	1
Clarke, ID	1
Sacher, AG	1
Graham, J	1
Bellows, DS	1
Ling, EK	1
Ward, RJ	1
Jamieson, LG	1
Tyers, M	1
Dirks, PB	1
Hasinoff, BB	1
Liang, H	1
Wu, X	1
Guziec, LJ	1
Guziec, FS	1
Marshall, K	1
Yalowich, JC	1
Das, SG	1
Srinivasan, B	1
Hermanson, DL	1
Bleeker, NP	1
Doshi, JM	1
Tang, R	1
Beck, WT	1
Xing, C	1
Lee, CC	1
Huang, KF	1
Chang, DM	1
Hsu, JJ	1
Huang, FC	1
Shih, KN	1
Chen, CL	1
Chen, TC	1
Chen, RH	1
Lin, JJ	1
Huang, HS	1
DeBono, A	1
Capuano, B	1
Scammells, PJ	1
Zhou, S	1
Shang, Q	1
Ji, J	1
Luan, Y	1
Shi, M	1
Zhang, J	1
Wang, Y	4
Han, Y	2
Zhao, X	2
Hu, H	2
Qiao, M	1
Chen, D	1
Di Micco, S	1
Di Sarno, V	1
Rossi, M	1
Vestuto, V	1
Konno, T	1
Novi, S	1
Tecce, MF	1
Napolitano, V	1
Ciaglia, T	1
Vitale, A	1
Gomez-Monterrey, IM	1
Bifulco, G	1
Bertamino, A	1
Ostacolo, C	1
Blasi, P	1
Fasano, A	1
Campiglia, P	1
Musella, S	1
Chen, T	1
Xu, J	2
Zhu, L	1
Yan, D	1
Ehrhardt, MJ	1
Leerink, JM	1
Mulder, RL	1
Mavinkurve-Groothuis, A	1
Kok, W	1
Nohria, A	1
Nathan, PC	1
Merkx, R	1
de Baat, E	1
Asogwa, OA	1
Skinner, R	1
Wallace, H	1
Lieke Feijen, EAM	1
de Ville de Goyet, M	1
Prasad, M	1
Bárdi, E	1
Pavasovic, V	1
van der Pal, H	1
Fresneau, B	1
Demoor-Goldschmidt, C	1
Hennewig, U	1
Steinberger, J	1
Plummer, C	1
Chen, MH	1
Teske, AJ	1
Haddy, N	1
van Dalen, EC	2
Constine, LS	1
Chow, EJ	1
Levitt, G	1
Hudson, MM	1
Kremer, LCM	2
Armenian, SH	1
Sun, J	2
Li, M	1
Lin, K	1
Liu, Z	1
Wang, Z	2
Wang, W	1
Zhao, Y	1
Zhen, Y	1
Zhang, S	2
Zhou, M	1
Tian, B	1
Bu, Y	1
Wu, Z	1
Yu, J	1
Wang, S	1
Sun, X	1
Zhu, X	1
Zhou, H	1
Kouwenberg, TW	1
Feijen, EAM	1
Netea, SA	1
Bolier, M	1
Slieker, MG	1
Hoesein, FAAM	1
Grotenhuis, HB	1
Mavinkurve-Groothuis, AMC	1
Biniari, G	1
Markatos, C	1
Nteli, A	1
Tzoupis, H	1
Simal, C	1
Vlamis-Gardikas, A	1
Karageorgos, V	1
Pirmettis, I	1
Petrou, P	1
Venihaki, M	1
Liapakis, G	1
Tselios, T	1
Kim, H	1
Jung, I	1
Lee, CH	1
An, J	1
Ko, M	1
Azuma, Y	1
Suzuki, K	1
Higai, K	1
Matsumoto, K	1
Tada, S	1
Mei, KC	1
Liao, YP	1
Jiang, J	1
Chiang, M	1
Khazaieli, M	1
Liu, X	1
Wang, X	1
Liu, Q	1
Chang, CH	1
Zhang, X	3
Li, J	2
Ji, Y	1
Melano, B	1
Telesca, D	1
Xia, T	1
Meng, H	1
Nel, AE	1
Al-Mugotir, M	1
Lovelace, JJ	1
George, J	1
Bessho, M	1
Pal, D	1
Struble, L	1
Kolar, C	1
Rana, S	1
Natarajan, A	1
Bessho, T	1
Borgstahl, GEO	1
Gomez-Sarosi, L	1
Sun, Y	1
Coleman, I	1
Bianchi-Frias, D	1
Nelson, PS	1
Sargazi, A	1
Kamali, N	1
Shiri, F	1
Heidari Majd, M	2
Wani, A	1
Savithra, GHL	1
Abyad, A	1
Kanvinde, S	1
Brock, S	1
Oupický, D	1
Subramaniam, V	1
Chuang, G	1
Xia, H	1
Burn, B	1
Bradley, J	1
Maderdrut, JL	1
Coy, DH	1
Varner, KJ	1
Mirzaei, SA	1
Gholamian Dehkordi, N	1
Ghamghami, M	1
Amiri, AH	1
Dalir Abdolahinia, E	1
Elahian, F	1
Masarapu, H	1
Patel, BK	1
Chariou, PL	1
Gulati, NM	1
Carpenter, BL	1
Ghiladi, RA	1
Shukla, S	4
Steinmetz, NF	1
Li, X	1
Yu, S	1
Lee, D	1
Kim, G	1
Lee, B	1
Cho, Y	1
Zheng, BY	1
Ke, MR	1
Huang, JD	1
Nam, KT	1
Chen, X	1
Yoon, J	1
Bezu, L	1
Sauvat, A	1
Humeau, J	1
Gomes-da-Silva, LC	1
Iribarren, K	1
Forveille, S	1
Garcia, P	1
Zhao, L	1
Liu, P	2
Zitvogel, L	4
Senovilla, L	3
Kepp, O	4
Kroemer, G	4
Jafarizad, A	1
Taghizadehgh-Alehjougi, A	1
Eskandani, M	1
Hatamzadeh, M	1
Abbasian, M	1
Mohammad-Rezaei, R	1
Mohammadzadeh, M	1
Toğar, B	1
Jaymand, M	1
Alev, M	1
Egenberger, L	1
Mühleisen, L	1
Weigel, B	1
Frey, B	1
Friedrich, RP	1
Pöttler, M	1
Alexiou, C	3
Janko, C	2
Ji, N	1
Yang, Y	2
Cai, CY	1
Lei, ZN	1
Wang, JQ	1
Gupta, P	1
Ambudkar, SV	4
Kong, D	1
Chen, ZS	3
Yoon, JH	1
Cho, HJ	1
Jin, HE	1
Maeng, HJ	1
Sun, M	1
Liu, T	1
Tan, X	1
Zhang, H	1
He, Z	1
Zhang, F	1
Peng, F	1
Qin, L	1
Yang, D	1
Li, R	1
Jiang, S	1
He, H	1
Zhang, P	1
Saw, PE	1
Yao, H	1
Lin, C	1
Tao, W	1
Farokhzad, OC	1
Xu, X	1
Tietze, R	2
Lyer, S	2
Dürr, S	2
Struffert, T	1
Engelhorn, T	1
Schwarz, M	1
Eckert, E	1
Göen, T	1
Vasylyev, S	1
Peukert, W	1
Wiekhorst, F	1
Trahms, L	1
Dörfler, A	1
Patel, KJ	1
Trédan, O	2
Tannock, IF	2
Sukkurwala, AQ	2
Martins, I	3
Schlemmer, F	2
Ruckenstuhl, C	1
Durchschlag, M	1
Michaud, M	3
Sistigu, A	1
Ma, Y	2
Vacchelli, E	2
Sulpice, E	1
Gidrol, X	1
Madeo, F	1
Galluzzi, L	2
Grandhi, TS	1
Potta, T	1
Taylor, DJ	1
Tian, Y	1
Johnson, RH	1
Meldrum, DR	1
Rege, K	1
Ghanbarzadeh, S	1
Arami, S	1
Pourmoazzen, Z	1
Ghasemian-Yadegari, J	1
Khorrami, A	1
Ottone, T	1
Hasan, SK	1
Voso, MT	1
Ledda, A	1
Montefusco, E	1
Fenu, S	1
Pagoni, M	1
Hubmann, M	1
Lunghi, M	1
Platzbecker, U	1
Lo-Coco, F	1
Weissenstein, U	1
Kunz, M	1
Urech, K	1
Baumgartner, S	1
Yang, J	1
Shi, Y	1
Li, C	2
Gui, L	1
Han, X	1
Song, Y	1
Li, N	1
Du, P	1
Zagotto, G	1
Gianoncelli, A	1
Sissi, C	1
Marzano, C	1
Gandin, V	1
Pasquale, R	1
Capranico, G	1
Ribaudo, G	1
Palumbo, M	1
Alpay, K	1
Farshchian, M	1
Tuomela, J	1
Sandholm, J	1
Aittokallio, K	1
Siljamäki, E	1
Kallio, M	1
Kähäri, VM	1
Hietanen, S	1
Garg, AD	1
Elsen, S	1
Krysko, DV	1
Vandenabeele, P	1
de Witte, P	1
Agostinis, P	1
Karthikeyan, C	1
Malla, R	1
Ashby, CR	2
Amawi, H	1
Abbott, KL	1
Moore, J	1
Chen, J	1
Balch, C	1
Lee, C	1
Flannery, PC	1
Trivedi, P	1
Faridi, JS	1
Pondugula, SR	1
Tiwari, AK	1
Abu Saleh, M	1
Solayman, M	1
Hoque, MM	1
Khan, MA	1
Sarwar, MG	1
Halim, MA	1
Buttmann, M	1
Seuffert, L	1
Mäder, U	1
Toyka, KV	1
Saha, C	1
Kaushik, A	1
Das, A	1
Pal, S	1
Majumder, D	1
Atwal, M	1
Lishman, EL	1
Austin, CA	1
Cowell, IG	1
Zhang, GN	1
Zhang, YK	1
Wang, YJ	1
Barbuti, AM	1
Zhu, XJ	1
Yu, XY	1
Wen, AW	1
Wurpel, JND	1
Cui, J	1
Wang, C	1
Wang, J	1
Li, Y	1
Zhang, L	2
Guo, W	1
Garbens, AB	1
Lalani, AS	1
Lemos, C	1
Kathmann, I	1
Giovannetti, E	1
Beliën, JA	1
Scheffer, GL	1
Calhau, C	1
Jansen, G	1
Peters, GJ	1
Kulcsár, G	1
Beuttler, J	1
Rothdiener, M	1
Müller, D	1
Frejd, FY	1
Kontermann, RE	1
Peng, H	2
Dong, Z	2
Qi, J	2
Liu, Y	1
Li, Z	1
Zhang, JT	2
Halldén, G	1
Tesniere, A	1
Séror, C	1
Métivier, D	1
Perfettini, JL	1
Cao, C	1
Ren, Y	1
Resta, LP	1
Pili, R	1
Eisenberger, MA	1
Spitz, A	1
King, S	1
Porter, J	1
Franke, A	1
Boinpally, R	1
Carducci, MA	1
Sweeney, CJ	1
Homolya, L	1
Orbán, TI	1
Csanády, L	1
Sarkadi, B	1
An, G	1
Wu, F	1
Morris, ME	1
Vehreschild, MJ	1
Meissner, AM	1
Cornely, OA	1
Maschmeyer, G	1
Neumann, S	1
von Lilienfeld-Toal, M	1
Karthaus, M	1
Wattad, M	1
Staib, P	1
Hellmich, M	1
Christ, H	1
Vehreschild, JJ	1
Schwartz, C	1
Kapoor, K	1
Kouanda, A	1
Adjemian, S	1
Pellegatti, P	1
Shen, S	1
Scoazec, M	1
Mignot, G	1
Rello-Varona, S	1
Tailler, M	1
Menger, L	1
Ghiringhelli, F	1
di Virgilio, F	1
Golubovskaya, VM	1
Ho, B	1
Zheng, M	1
Magis, A	1
Ostrov, D	1
Cance, WG	1
Takara, K	1
Yamamoto, K	1
Matsubara, M	1
Minegaki, T	1
Takahashi, M	1
Yokoyama, T	1
Okumura, K	1
Mann, J	1
Schreiber, E	1
Herrmann, M	1
Guo, S	1
Fan, R	1
Yu, M	1
Li, F	1
Zhu, C	1
Gan, Y	1
Spugnini, EP	1
Fanciulli, M	1
Citro, G	1
Baldi, A	1
Asgari, D	1
Barar, J	1
Valizadeh, H	1
Kafil, V	1
Coukos, G	1
Omidi, Y	1
Yu, W	1
Pirollo, KF	1
Yu, B	1
Rait, A	1
Xiang, L	1
Huang, W	1
Zhou, Q	1
Ertem, G	1
Chang, EH	1
Blokhin, DIu	1
Hamilton, D	1
Batist, G	1
Cartei, G	2
Contessi, E	1
Comelli, M	1
Turrin, D	1
Toso, C	1
Sibau, A	2
Mian, S	2
Bramezza, M	1
Marchion, DC	1
Bicaku, E	1
Turner, JG	1
Daud, AI	1
Sullivan, DM	1
Munster, PN	1
Liu, W	1
Zhang, Z	1
Huang, Y	1
Koceva-Chyła, A	1
Wiecławska, B	1
Jóźwiak, Z	1
Bryszewska, M	1
Limtrakul, P	1
Shi, Z	1
Peng, XX	1
Kim, IW	1
Si, QS	1
Robey, RW	1
Bates, SE	2
Shen, T	1
Fu, LW	1
Vahid, B	1
Marik, PE	1
Calcagno, AM	1
Fostel, JM	1
To, KK	1
Salcido, CD	1
Martin, SE	1
Chewning, KJ	1
Wu, CP	1
Varticovski, L	1
Caplen, NJ	1
Lebrun, C	1
Debouverie, M	1
Vermersch, P	1
Clavelou, P	1
Rumbach, L	1
de Seze, J	1
Wiertlevski, S	1
Defer, G	1
Gout, O	1
Berthier, F	1
Danzon, A	1
Moser, K	1
Pohl, A	1
Mathé, G	1
Lathan, B	1
Von Hoff, DD	8
Elslager, E	1
Crossley, RJ	1
Ogawa, M	3
Tada, A	1
Usui, N	1
Inagaki, J	1
Horikoshi, N	1
Inoue, K	1
Ikeda, K	1
Adachi, K	1
Nakada, H	1
Okada, Y	1
Klener, P	1
Goldsmith, MA	1
Ohnuma, T	1
Jaffrey, IH	1
Greenspan, EM	1
Holland, JF	1
De Jager, R	1
Cappelaere, P	1
Armand, JP	2
Keiling, R	1
Fargeot, P	1
Bastit, P	1
van Glabbeke, M	1
Renard, J	1
Earl, H	1
Rubens, R	1
Loesch, DM	1
Kuhn, J	1
Coltman, CA	1
Tio, F	1
Chaudhuri, TK	1
Bender, JF	1
Grillo-Lopez, AJ	1
Cowan, JD	1
Clark, GM	3
Hagenberg, L	1
Loynds, P	1
Nagel, GA	1
Unverferth, DV	1
Unverferth, BJ	1
Balcerzak, SP	1
Bashore, TA	1
Neidhart, JA	1
Anderson, KC	2
Garnick, MB	2
Meshad, MW	1
Cohen, GI	2
Pegg, WJ	1
Frei, E	1
Israel, M	1
Modest, E	1
Canellos, GP	1
Macdonald, JS	1
Marsoni, S	1
Bruno, S	1
Poster, D	1
Wynert, WR	1
Harvey, HA	1
Lipton, A	1
Schweitzer, J	1
White, DS	1
Stewart, JA	1
McCormack, JJ	1
Krakoff, IH	1
Savaraj, N	1
Lu, K	1
Manuel, V	1
Loo, TL	1
Stuart-Harris, RC	1
Smith, IE	2
Piccart, M	1
Rozencweig, M	2
Abele, R	1
Cumps, E	1
Dodion, P	1
Dupont, D	1
Kisner, D	1
Kenis, Y	2
Alberts, DS	5
Griffith, KS	1
Goodman, GE	1
Herman, TS	1
Murray, E	1
Maiche, AG	1
Clark, RE	1
Shlebak, AA	1
Creagh, MD	1
Domenech, J	1
Linassier, C	1
Gihana, E	1
Dayan, A	1
Truglio, D	1
Bout, M	1
Petitdidier, C	1
Delain, M	1
Petit, A	1
Brémond, JL	1
de Forni, M	2
Ogilvie, GK	4
Moore, AS	4
Chen, C	1
Ciekot, PA	1
Atwater, SW	2
Bergman, PJ	1
Walters, LM	1
Schiller, JH	1
Storer, B	1
Arzoomanian, R	1
Tutsch, K	1
Alberti, D	1
Spriggs, D	1
Stiff, PJ	2
McKenzie, RS	1
Sosman, JA	1
Dolan, JR	1
Rad, N	2
McCloskey, T	2
Obradovich, JE	3
Elmslie, RE	3
Vail, DM	3
Straw, RC	3
Salmon, MD	1
Klein, MK	1
Ciekot, PE	1
Görich, J	1
Brensing, KA	1
Kunze, V	1
Sokiranski, R	1
Rilinger, N	1
Müller-Miny, H	1
Brambs, HJ	1
Fleming, GF	1
Janisch, L	1
Vogelzang, NJ	1
Vokes, EE	1
Ratain, MJ	1
Meisenberg, BR	1
Miller, WE	1
McMillan, R	1
Peacock, NW	1
Burris, HA	1
Dieras, V	1
Smith, L	1
Rodriguez, GI	1
Eckardt, JR	1
Jones, SF	1
Hardy, J	1
Hohneker, J	1
Bigley, J	1
Bayer, R	1
Tan, S	1
Camarda, M	1
Sosman, J	1
Peace, D	1
Kinch, L	1
Loutfi, S	1
Hande, KR	1
Adlakha-Hutcheon, G	1
Bally, MB	1
Shew, CR	1
Madden, TD	1
Joseph, CD	1
Praveenkumar, V	1
Kuttan, G	1
Kuttan, R	1
Dalle, JH	1
Lambilliotte, A	1
Defachelles, AS	1
Mazingue, F	1
Nelken, B	1
Caponigro, F	1
Avallone, A	1
Rivellini, F	1
Comella, P	1
Ionna, F	1
De Rosa, V	1
Comella, G	1
Pérez-Gracia, JL	1
Colomer, R	1
Ruiz-Casado, A	1
Arcediano, A	1
Tornamira, MV	1
Gómez-Martin, C	1
Valentin, V	1
Mendiola, C	1
Cortés-Funes, H	1
Hornedo, J	1
Richard, B	2
Launay-Iliadis, MC	1
Iliadis, A	2
Just-Landi, S	1
Blaise, D	1
Stoppa, AM	1
Viens, P	1
Gaspard, MH	1
Maraninchi, D	1
Cano, JP	1
Groth, G	1
Gatzemeier, U	1
Häussingen, K	1
Heckmayr, M	1
Magnussen, H	1
Neuhauss, R	1
Pavel, JV	1
Faulds, D	1
Balfour, JA	1
Chrisp, P	1
Langtry, HD	1
Gasparini, G	1
Dal Fior, S	1
Pozza, F	1
Panizzoni, GA	1
Favretto, S	1
Loeffler, TM	1
Weber, FW	1
Hausamen, TU	1
Kreisle, WH	1
List, AF	1
Plezia, P	1
Peng, YM	2
George, M	1
Birchall, LA	1
Bailey, NP	1
Blackledge, GR	1
Nanninga, AG	1
de Vries, EG	6
Willemse, PH	5
Oosterhuis, BE	1
Sleijfer, DT	3
Hoekstra, HJ	1
Mulder, NH	4
Lachau, S	1
Huguet, F	1
Canal, P	1
Laurent, G	1
Chevreau, C	1
Roche, H	1
Bugat, R	1
Ellis, ED	1
Williams, SF	1
Moormeier, JA	1
Kaminer, LS	1
Bitran, JD	1
Curtis, CR	1
Dickinson, K	2
Cooper, MF	2
Withrow, SJ	2
Hu, OY	1
Chang, SP	1
Song, YB	1
Chen, KY	1
Law, CK	1
Bernard, MS	1
Hayward, M	1
Hayward, C	1
Mundy, L	1
LeMaistre, CF	2
Herzig, R	1
Markman, M	1
Weiss, GR	1
Marshall, MH	1
Buchok, JB	1
Knight, WA	1
Wunz, TP	1
Dorr, RT	1
Tunget, CL	1
Einspahr, J	1
Milton, S	1
Remers, WA	1
Mulder, PO	2
Bouman, JG	1
Gietema, JA	1
Van Rijsbergen, H	1
Van der Geest, S	1
Uges, DR	3
Launay, MC	1
Brito-Babapulle, F	1
Barbatis, C	1
Whitmore, DN	1
Pouillart, P	1
Beuzeboc, P	1
Dorval, T	1
Garcia-Giralt, E	1
Jouve, M	1
Palangie, T	1
School, S	1
Weiss, RB	1
Smith, WJ	1
Muss, HB	1
Capizzi, RL	1
White, DR	1
Richards, F	1
Jackson, DV	1
Powell, BL	1
Zekan, PJ	1
Greidanus, J	3
Oosterhuis, B	1
Mather, FJ	1
Simon, RM	1
Koeller, J	1
Eble, M	1
Oremus, ET	1
De Langen, ZJ	2
Fleming, TR	1
Okuma, K	1
Ariyoshi, Y	1
Ota, K	1
Cendron, R	1
Lamon, S	1
Clocchiatti, L	1
Fasola, G	1
Galletti, D	1
Lazarus, HM	1
Berger, NA	1
Nieweg, MB	1
Poirier, TI	1
Shenkenberg, TD	1
Pratt, CB	1
Vietti, TJ	1
Etcubanas, E	1
Sexauer, C	1
Krance, RA	1
Mahoney, DH	1
Patterson, RB	1
Smyth, JF	1
Macpherson, JS	1
Warrington, PS	1
Leonard, RC	1
Wolf, CR	1
Van Belle, SJ	1
de Planque, MM	1
van Oosterom, AT	1
Schoemaker, TJ	1
Deneve, W	1
McVie, JG	1
Stewart, DJ	1
Green, RM	1
Mikhael, NZ	1
Montpetit, V	1
Thibault, M	1
Maroun, JA	1
Vorobiof, DA	1
Iturralde, M	1
Falkson, G	1
Leigh, S	1
Davis, TP	1
Woodward, DL	1
DuKart, G	1
Iatropoulos, MJ	1
Yacobi, A	1
Klein, HO	1
Sanders, C	1
Rombaut, W	1
Crespeigne, N	1
Klastersky, J	1